SCHEMBL693965

SCHEMBL693965

CN[C@H](CO)Cc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.57
CYP3A4 P08684 1/20 0.57
TAAR1 Q96RJ0 2/20 0.55
SLC18A2 Q05940 1/20 0.55
SIGMAR1 Q99720 1/20 0.55
TRPA1 O75762 1/20 0.53
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
MAPT P10636 1/20 0.51
KMT2A Q03164 1/20 0.51
OPRD1 P41143 2/20 0.48
OPRK1 P41145 2/20 0.48
EPHX1 P07099 1/20 0.47
OPRM1 P35372 1/20 0.46
ROCK2 O75116 1/20 0.44
RPS6KA5 O75582 1/20 0.44
RPS6KA4 O75676 1/20 0.44
PRKACA P17612 1/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1908735 1.00 MAPK1 (0.57) MAPK1CYP3A4TAAR1SLC18A2SIGMAR1
SCHEMBL1396350 1.00 MAPK1 (0.57) MAPK1CYP3A4TAAR1SLC18A2SIGMAR1
Carbamic Acid SCHEMBL28108902 0.91 MAPK1 (0.58) MAPK1CYP3A4TAAR1SLC18A2SIGMAR1
SCHEMBL1697045 0.87 SIGMAR1 (0.64) TAAR1SLC18A2SIGMAR1EPHX1OPRM1
SCHEMBL2293359 0.85 ACACB (0.47) MAPK1CYP3A4TAAR1SLC18A2SIGMAR1
SCHEMBL2293880 0.85 ACACB (0.47) MAPK1CYP3A4TAAR1SLC18A2SIGMAR1
SCHEMBL7345520 0.85 MAPK1 (0.58) MAPK1CYP3A4SIGMAR1TRPA1KDM4E
SCHEMBL7348151 0.85 MAPK1 (0.58) MAPK1CYP3A4SIGMAR1TRPA1KDM4E
SCHEMBL12992873 0.84 MAPK1 (0.44) MAPK1CYP3A4TAAR1SLC18A2SIGMAR1
SCHEMBL12379288 0.84 LTA4H (0.53) MAPK1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109721-A1 IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON: SYNTHESIS AND LNP FORMULATION ALDEXCHEM KFT (HU) 2026-04-23 US disclosed
EP-4646422-A1 IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON: SYNTHESIS AND LNP FORMULATION AldexChem Kft. (HU) 2025-11-12 EP disclosed
WO-2025052296-A1 IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON: SYNTHESIS AND LNP FORMULATION ALDEXCHEM KFT. (HU) 2025-03-13 WO disclosed
EP-4310093-A1 AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS, COMPRISING SAME Prazertherapeutics Inc. (KR) 2024-01-24 EP disclosed
US-20230312646-A1 ANTIBACTERIAL PEPTIDES Universite de Bordeaux (FR) 2023-10-05 US disclosed
WO-2023020789-A1 METHODS FOR PREPARING OXAZABOROLIDINES PATHWAY INTERMEDIATES LIMITED (GB) 2023-02-23 WO disclosed
US-10266506-B2 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PIRAMAL IMAGING SA (CH) 2019-04-23 US disclosed
US-10266506-B2 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PIRAMAL IMAGING SA (CH) 2019-04-23 US disclosed
EP-2630104-B1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM PIRAMAL IMAGING SA (CH) 2018-04-04 EP disclosed
EP-2630104-B1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM PIRAMAL IMAGING SA (CH) 2018-04-04 EP disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6350767-B1 GROWTH HORMONE RELEASE STIMULANT NOVO NORDISK A/S (DK) 2002-02-26 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-6013658-A ANIMAL GROWTH REGULATORS NOVO NORDISK A/S (DK) 2000-01-11 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
EP-0805816-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-11-12 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed
WO-1996022997-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1996-08-01 WO disclosed
WO-1994007841-A1 PROCESS FOR REDUCING CARBOXYLIC ACIDS OR CARBOXYLIC ACID DERIVATIVES, AND NOVEL COMPOUNDS DEGUSSA AKTIENGESELLSCHAFT (DE) 1994-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10266506-B2 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PMP22, MEN1, VHL MAPK1 2939/4885CYP3A4 4602/4885TAAR1 642/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR MAPK1 1036/4885CYP3A4 3566/4885TAAR1 481/4885
US-20260109721-A1 IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON: SYNTHESIS AND LNP FORMULATION SGMS1, SGMS2, AGO2 MAPK1 2335/4885CYP3A4 4841/4885TAAR1 3695/4885
US-20230312646-A1 ANTIBACTERIAL PEPTIDES VIP, NRDC, CLPP MAPK1 2451/4885CYP3A4 4695/4885TAAR1 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.